Spiroindolone KAE609 for Falciparum and Vivax Malaria

Ítems similars

• A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel spiroindolone KAE609, to assess the safety, tolerability and pharmacokinetics in healthy adult volunteers
  per: Leong, Joel, et al.
  Publicat: (2014)
• A First-in-Human Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Oral Dose Study of Novel Antimalarial Spiroindolone KAE609 (Cipargamin) To Assess Its Safety, Tolerability, and Pharmacokinetics in Healthy Adult Volunteers
  per: Leong, F. Joel, et al.
  Publicat: (2014)
• The Spiroindolone KAE609 Does Not Induce Dormant Ring Stages in Plasmodium falciparum Parasites
  per: Chavchich, Marina, et al.
  Publicat: (2016)
• Pharmacokinetic-Pharmacodynamic Analysis of Spiroindolone Analogs and KAE609 in a Murine Malaria Model
  per: Lakshminarayana, Suresh B., et al.
  Publicat: (2015)
• A Basis for Rapid Clearance of Circulating Ring-Stage Malaria Parasites by the Spiroindolone KAE609
  per: Zhang, Rou, et al.
  Publicat: (2016)